Unlocking the potential of agonist antibodies for treating cancer using antibody engineering

Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025 Rabia, 2018, Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility, Biochem. Eng. J., 137, 365, 10.1016/j.bej.2018.06.003 Mullard, 2021, FDA approves 100th monoclonal antibody product, Nat. Rev. Drug Discov., 20, 491, 10.1038/d41573-021-00079-7 Mayes, 2018, The promise and challenges of immune agonist antibody development in cancer, Nat. Rev. Drug Discov., 17, 509, 10.1038/nrd.2018.75 Schardt, 2022, Agonist antibody discovery: experimental, computational, and rational engineering approaches, Drug Discov. Today, 27, 31, 10.1016/j.drudis.2021.09.008 Watts, 2005, TNF/TNFR family members in costimulation of T cell responses, Annu. Rev. Immunol., 23, 23, 10.1146/annurev.immunol.23.021704.115839 Sedger, 2014, TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants – past, present and future, Cytokine Growth Factor Rev., 25, 453, 10.1016/j.cytogfr.2014.07.016 Brenner, 2015, Regulation of tumour necrosis factor signalling: live or let die, Nat. Rev. Immunol., 15, 362, 10.1038/nri3834 Furness, 2014, Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies, Trends Immunol., 35, 290, 10.1016/j.it.2014.05.002 Yang, 2019, Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members, mAbs, 11, 996, 10.1080/19420862.2019.1625662 Kucka, 2020, Receptor oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily, Front. Cell. Dev. Biol., 8 Tigue, 2017, MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential, Oncoimmunology, 6, 10.1080/2162402X.2017.1280645 Sadeghnezhad, 2019, Identification of new DR5 agonistic nanobodies and generation of multivalent nanobody constructs for cancer treatment, Int. J. Mol. Sci., 20, 4818, 10.3390/ijms20194818 Greer, 2019, MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer, Breast Cancer Res., 21, 27, 10.1186/s13058-019-1116-1 Wang, 2021, Multimeric anti-DR5 IgM agonist antibody IGM-8444 is a potent inducer of cancer cell apoptosis and synergizes with chemotherapy and BCL-2 inhibitor ABT-199, Mol. Cancer Ther., 20, 2483, 10.1158/1535-7163.MCT-20-1132 Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J. Clin. Oncol., 34, 3119, 10.1200/JCO.2016.67.9761 Huang, 2020, Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy, J. Cancer Res. Clin. Oncol., 146, 3111, 10.1007/s00432-020-03404-6 Brünker, 2016, RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven DR5 hyperclustering and tumor cell apoptosis, Mol. Cancer Ther., 15, 946, 10.1158/1535-7163.MCT-15-0647 Ishihara, 2018, Improving efficacy and safety of agonistic anti-CD40 antibody through extracellular matrix affinity, Mol. Cancer Ther., 17, 2399, 10.1158/1535-7163.MCT-18-0091 Gaspar, 2020, CD137/OX40 bispecific antibody induces potent antitumor activity that is dependent on target coengagement, Cancer Immunol. Res., 8, 781, 10.1158/2326-6066.CIR-19-0798 Warwas, 2021, Co-stimulatory bispecific antibodies induce enhanced T cell activation and tumor cell killing in breast cancer models, Front. Immunol., 12, 10.3389/fimmu.2021.719116 Chan, 2022, An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy, Nat. Cancer, 3, 337, 10.1038/s43018-022-00334-9 Compte, 2021, An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity, Clin. Cancer Res., 27, 3167, 10.1158/1078-0432.CCR-20-4625 Claus, 2019, Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy, Sci. Transl. Med., 11, 10.1126/scitranslmed.aav5989 Kvarnhammar, 2019, The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation, J. Immunother. Cancer, 7, 103, 10.1186/s40425-019-0570-8 Dillon, 2008, Structural and functional characterization of disulfide isoforms of the human IgG2 subclass, J. Biol. Chem., 283, 16206, 10.1074/jbc.M709988200 Liu, 2019, Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility, Nat. Commun., 10, 4206, 10.1038/s41467-019-12097-6 Yu, 2020, Isotype switching converts anti-CD40 antagonism to agonism to elicit potent antitumor activity, Cancer Cell, 37, 850, 10.1016/j.ccell.2020.04.013 Segal, 2018, Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer, Clin. Cancer Res., 24, 1816, 10.1158/1078-0432.CCR-17-1922 Gopal, 2020, First-in-human study of utomilumab, a 4-1BB/CD137 agonist, in combination with rituximab in patients with follicular and other CD20(+) non-Hodgkin lymphomas, Clin. Cancer Res., 26, 2524, 10.1158/1078-0432.CCR-19-2973 Vonderheide, 2007, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody, J. Clin. Oncol., 25, 876, 10.1200/JCO.2006.08.3311 Vonderheide, 2013, Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors, Oncoimmunology, 2, 10.4161/onci.23033 Junker, 2020, Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation, Front. Immunol., 11, 1393, 10.3389/fimmu.2020.01393 Li, 2012, Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement, Proc. Natl. Acad. Sci., 109, 10966, 10.1073/pnas.1208698109 Dahan, 2016, Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcγR engagement, Cancer Cell, 29, 820, 10.1016/j.ccell.2016.05.001 Mimoto, 2013, Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131, Protein Eng. Des. Sel., 26, 589, 10.1093/protein/gzt022 Campos Carrascosa, 2020, FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells, J. Immunother. Cancer, 8, 10.1136/jitc-2020-000816 Zhang, 2016, Fc engineering approaches to enhance the agonism and effector functions of an anti-OX40 antibody, J. Biol. Chem., 291, 27134, 10.1074/jbc.M116.757773 Overdijk, 2020, Dual epitope targeting and enhanced hexamerization by DR5 antibodies as a novel approach to induce potent antitumor activity through DR5 agonism, Mol. Cancer Ther., 19, 2126, 10.1158/1535-7163.MCT-20-0044 Zhang, 2017, Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization, mAbs, 9, 1129, 10.1080/19420862.2017.1358838 Bulliard, 2014, OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy, Immunol. Cell Biol., 92, 475, 10.1038/icb.2014.26 Buchan, 2018, Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function, Immunity, 49, 958, 10.1016/j.immuni.2018.09.014 Qi, 2019, Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity, Nat. Commun., 10, 2141, 10.1038/s41467-019-10088-1 van der Horst, 2021, Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma, Blood Adv., 5, 2165, 10.1182/bloodadvances.2020003731 Yu, 2018, Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies, Cancer Cell, 33, 664, 10.1016/j.ccell.2018.02.009 Chin, 2018, Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab, Nat. Commun., 9, 4679, 10.1038/s41467-018-07136-7 Segal, 2017, Results from an integrated safety analysis of urelumab, an agonist Anti-CD137 monoclonal antibody, Clin. Cancer Res., 23, 1929, 10.1158/1078-0432.CCR-16-1272 Tolcher, 2017, Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors, Clin. Cancer Res., 23, 5349, 10.1158/1078-0432.CCR-17-1243 Griffiths, 2020, Domain binding and isotype dictate the activity of anti-human OX40 antibodies, J. Immunother. Cancer, 8, 10.1136/jitc-2020-001557 Zhang, 2019, Ligand-blocking and membrane-proximal domain targeting anti-OX40 antibodies mediate potent T cell-stimulatory and anti-tumor activity, Cell Rep., 27, 3117, 10.1016/j.celrep.2019.05.027 Nordstrom, 2011, Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties, Breast Cancer Res., 13, R123, 10.1186/bcr3069 Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J. Clin. Oncol., 28, 3167, 10.1200/JCO.2009.26.7609 Wang, 2019, An integrative approach to inform optimal administration of OX40 agonist antibodies in patients with advanced solid tumors, Clin. Cancer Res., 25, 6709, 10.1158/1078-0432.CCR-19-0526 Stebbings, 2007, “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics, J. Immunol., 179, 3325, 10.4049/jimmunol.179.5.3325 Waibler, 2008, Toward experimental assessment of receptor occupancy: TGN1412 revisited, J. Allergy Clin. Immunol., 122, 890, 10.1016/j.jaci.2008.07.049 Gutierrez, 2021, OX40 Agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors, Clin. Cancer Res., 27, 460, 10.1158/1078-0432.CCR-20-1830